Innoforce, a global development and biomanufacturing company focused on advanced therapy medicinal products (ATMPs), and Hibiscus BioVentures, a firm committed to building patient-focused companies around transformative technologies, have formed a partnership to leverage the combined resources of both organizations to advance new ATMPs and biologic medicines in order to accelerate development of Hibiscus BioTechnology Studio Companies’ product pipeline.

“This strategic partnership with Innoforce underscores our commitment to the growing pipeline of Hibiscus Studio Companies, enhancing our operational capabilities and facilitating the development and commercialization of innovative medicines,” said Chris Jeffers, CEO, Hibiscus BioTechnology.

Yuling Li, CEO, Innoforce, said, “We are excited to partner with Hibiscus, which brings a highly experienced team and unique model to develop new technologies that address important unmet medical needs. The partnership will leverage our drug development experience with Hibiscus’ pipeline initiatives in alignment with Innoforce’s mission to enable global development of novel, advanced biotherapeutics.”